ArticlemSphere
Optimized CRISPR-Cas9 Genome Editing for
Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 78 citations in OpenAlex.
- A comprehensive review of CRISPR-Cas9-mediated genome editing in Leishmania strains: methodologies, applications, challenges and future directions.Molecular biology reports · 2026Review
- Chemical genetics reveals Leishmania KKT2 and CRK9 kinase activity is required for cell cycle progression.PLoS pathogens · 2026Article
- Precision Without Selection: A Marker-Free CRISPR/Cas9-Based Protocol for Multiplexed Genome Editing in Trypanosomatids.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Translesion synthesis and microhomology-mediated end-joining repair in trypanosomatids.PLoS neglected tropical diseases · 2025Review
- Article
- Current trends in application of CRISPR/Cas9 in gene editing and diagnostics in Neglected tropical diseases (NTDs).Molecular biology reports · 2025Review
- Article
- Recent Advances in CRISPR/Cas9-Mediated Genome Editing in Leishmania Strains.Acta parasitologica · 2024Review
- Synthetic biology for combating leishmaniasis.Frontiers in microbiology · 2024Article
- Evidence for gene essentiality in Leishmania using CRISPR.PloS one · 2024Article
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- Lentiviral Transduction-based CRISPR/Cas9 Editing ofCurrent genomics · 2023Article
- Guidelines for the purification and characterization of extracellular vesicles of parasites.Journal of extracellular biology · 2023Article
- Article
- Investigating theTropical medicine and infectious disease · 2022Article
- Article
- Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030.Frontiers in medicine · 2022Review
- Challenges and Tools for In VitroPathogens (Basel, Switzerland) · 2021Review
- The antioxidant response favors Leishmania parasites survival, limits inflammation and reprograms the host cell metabolism.PLoS pathogens · 2021Article
- Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of Leishmania donovani contributes to reduced virulence.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-Cas9-mediated genome editing has recently been adapted for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.